Navigation Links
Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
Date:11/19/2013

BOSTON, Nov. 19, 2013 /PRNewswire-iReach/ -- Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye.  Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.

"Patients are increasingly interested in non-invasive therapies to rejuvenate the face," said Jeffrey S. Dover, MD, FRCPC, a nationally recognized dermatologist and member of the Topokine's Scientific Board of Advisors.  "If approved, XAF5 Gel would provide a convenient topical medication that reduces submental fat."

XAF5 is a small molecule that induces a G protein-coupled cascade in adipocytes to reduce cellular lipid content and differentiation.  Daily administration of XAF5 reduces fat around the human eye and in five laboratory models.  The technology was first conceived by ophthalmologists at the Massachusetts Eye and Ear Infirmary / Harvard Medical School Department of Ophthalmology.

The Phase 2 study follows positive data from a 6-week Phase 1 clinical trial completed in April 2013.  In that randomized, double-blind, placebo-controlled study, 32 healthy men and women applied XAF5 Gel or placebo once a night to a 100 cm2 area of abdominal skin.  The study met its pre-specified primary safety and tolerability endpoint at all doses.  The only side effects were mild, temporary skin redness or itch, which occurred at similar rates with placebo.  Exploratory CT scans showed a dose-dependent reduction in fat volume under treated skin as compared to contralateral untreated skin.

 "We are excited to advance our XAF5 Gel program into Phase 2," said Topokine's Chief Scientific Officer, Michael Singer, MD, PhD.  "Our research shows that patients would prefer a topical fat-reducing medication over therapies that cut or puncture the skin, which are the only treatments currently available.  The submental region is one of several body areas that we plan to target." 

About Topokine

Topokine Therapeutics is a clinical-stage biotechnology company developing topical prescription medications for non-invasive contouring of the face and body.  The company's lead program, XAF5 Gel, is a topical adipomodulatory product in Phase 2 clinical development for local reduction of excess subcutaneous fat.  Topokine's pipeline also includes XAF5 Ointment to treat steatoblepharon ("eye bags") and TAT4, a topical "filler" therapy to increase local tissue volume.

About Submental Fat

The area under the chin, also called the submental region, is an important determinant of facial attractiveness and youthfulness. Excess submental fat is very common and contributes to the appearance known as "double chin."  People with excess submental fat are more likely to report feeling self-conscious or appearing older or overweight.  Currently, the only available therapies to reduce submental fat require cutting or puncturing the skin.

Forward-Looking Statements

This press release contains forward-looking statements regarding the development of XAF5 Gel.  These statements are based on Topokine's current beliefs and expectations, but actual results may differ.

Media Contact: Matt Burke, Topokine, 6033150618, matt.burke@topokine.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Topokine Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
3. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
4. Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences
5. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
6. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
7. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
8. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
9. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
10. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):